Actifio delivers Enterprise Data-as-a-Service to hundreds of global enterprise customers and service provider partners in more than 30 countries. Actifio helps hundreds of global enterprise customers and service provider partners in more than 30 countries around the world virtualize their data, just as they virtualized their servers and networks. Their Virtual Data Pipeline™ technology decouples data from infrastructure, enabling dramatic improvements in business resiliency, agility, and access to the cloud. Actifio replaces siloed data management applications with a radically simple, application-centric, SLA-driven approach that lets customers capture data from production applications, manage it more economically, and use it when and where they need. The result is enterprise data available for any use, anytime, anywhere, for less.
EndoGastric Solutions is a medical device company developing and commercializing innovative, evidence-based, incision-less surgical technology for the treatment of GERD.
Oasys (Osmotic Application Systems) is a privately held Boston, MA based company developing a suite of proprietary energy and resource recovery products to address the growing, global water crisis. Engineered Osmosisâ„¢ (EOâ„¢) is a platform for reducing cost in the production of clean water, power and energy through more efficient and sustainable utilization of resources.
Founded in 2009 by Marty Kagan and Julien Coulon, two veterans of web hosting and content delivery market, Cedexis optimizes web performance across data centers, delivery networks and clouds for companies that want to reach new global markets. With Cedexis, companies can comparatively assess worldwide cloud performance and availability for informed vendor selection and making cost-and-performance tradeoffs. Cedexis also provides adaptive automation for dynamically optimizing traffic across clouds, data centers and delivery networks to dynamically match the best-performing clouds with local demand. Since revenue conversions and brand experience are directly tied to online performance, media, retail and consumer branded companies rely on Cedexis to ensure 100% availability, fast page loads, downloads and transactions to drive traffic and revenue at lower cost and risk. Cedexis is headquartered in Portland (OR) and Paris (EMEA) with offices in San Francisco (CA), London (UK) and sales representatives in Germany, Japan, Israel and Brazil.
EndoGastric Solutions is a medical device company developing and commercializing innovative, evidence-based, incision-less surgical technology for the treatment of GERD.
Planful is the pioneer of financial performance management cloud software. The Planful platform is used by the Office of the CFO around the globe to streamline business-wide planning, budgeting, consolidations, reporting, and visual analytics. Planful empowers users to plan confidently, close faster, and report accurately. More than 1,000 customers, including Boston Red Sox, Del Monte, TGI Friday’s, and 23andMe, rely on Planful to accelerate cycle times, increase productivity, and improve accuracy across the end-to-end FP&A process. Planful is a private company backed by Vector Capital, a leading global private equity firm. Learn more at www.planful.com.
Valeritas is a medical technology company committed to developing and commercializing innovative drug delivery solutions that contribute to clinical and humanistic outcomes for patients, with an initial focus on the treatment of diabetes. Valeritas' medical technologies portfolio is headlined by the h-Patch technology. The first use of the h-Patch technology will be the V-Go disposable insulin delivery device for continuous delivery both at a preset basal rate and for on-demand bolus dosing at mealtimes. The V-Go is a simple-to-use, once-daily, disposable insulin delivery device that provides a preset basal rate and on-demand bolus dosing for mealtime coverage via a mealtime insulin. The V-Go will enable the millions suffering from Type 2 diabetes to conveniently and discreetly deliver insulin throughout the day bolus dose on-demand around mealtimes. The h-Patch technology is also being developed to serve as a launching platform for applications across a wide spectrum of medical needs.
EndoGastric Solutions is a medical device company developing and commercializing innovative, evidence-based, incision-less surgical technology for the treatment of GERD.
Nuvaira is a new alternative COPD treatment option that specializes in developing devices for treating lung diseases. Nuvaira is currently working on a novel catheter-based system that has the potential to improve lung function, exercise capacity, and quality of life for patients with chronic obstructive pulmonary disease. It was founded in 2008 and headquartered in Minneapolis, Minnesota.
PowerVision is a private company focused on developing a novel accommodating intraocular lens, which is designed to restore True AccommodationTM. Their innovative FluidVisionTM accommodating intraocular lens (IOL) is poised to help individuals affected by presbyopia and/or cataracts regain the ability to dynamically adjust focus for clear vision at all distances. Fifty years ago, vision correction surgery was changed forever by the invention of the intraocular lens, which is used to treat a cataract – a clouding and hardening of the dime-sized, normally clear, crystalline lens inside your eye which can rob you of your vision in your 60’s, 70’s and 80’s. PowerVision set out to dramatically improve vision correction surgery again. They began the development of their FluidVision IOL, which mimics the way a healthy eye works and can restore clear vision at all distances, near, far, and everywhere in between. It uses a tiny amount of fluid inside the lens and natural eye muscles to change shape and adjust focus just the way your healthy eye does. For the more than 20 million people with cataracts in the U.S. and, ultimately, the more than 90 million with Presbyopia – the loss of ability to focus up close that affects people in their 40’s and 50’s – the FluidVision lens can potentially give them freedom from ever needing glasses, contacts or any vision correction procedure again.
Catabasis Pharmaceuticals is a biopharmaceutical company located in Cambridge, Massachusetts focused on the discovery and development of innovative drugs to treat inflammatory conditions. Their platform technology enables the discovery and development of small molecules that simultaneously and specifically target pathways in the inflammatory response. The Catabasis platform will lead to the development of a novel mechanism of action therapies to safely and effectively treat inflammatory diseases.
Calithera Biosciences is a development-stage pharmaceutical company committed to discovering and developing novel small molecule therapeutics for the treatment of cancer. They are applying Their scientific expertise to build a pipeline of unique anti- cancer drugs that selectively target metabolic and apoptotic pathways critical to tumor growth and survival.
Fuze is a global, cloud-based unified communications platform that empowers productivity and delivers insights across the enterprise by enabling simplified business voice communications, flexible video conferencing, and always-on collaboration. Fuze allows the modern, mobile workforce to seamlessly communicate anytime, anywhere, across any device. Fuze was acquired by 8x8.
Second Genome’s mission is to transform lives with medicines developed through innovative microbiome science. Second Genome has built a novel platform for microbiome drug discovery. Second Genome has completed more than 400 microbiome studies, analyzing more than 75,000 samples, for internal R&D, as well as for external partners across government, academia, pharmaceutical, nutrition and industrial companies. The team leverages its microbiome analysis platform with its partners’ specific expertise to generate insightful findings that can accelerate research programs by elucidating the role of the microbiome in human health conditions, agriculture, animal health and other industries. The company has established a pipeline of therapeutic products for the treatment of inflammation and metabolic diseases.
Solar Junction is a manufacturer of high efficiency III-V multi-junction solar cells based on ASLAM ™ materials. The company is dedicated to providing the industry’s highest efficiency solar cells to enable CPV as a cost effective energy solution. Founded in 2007, Solar Junction is headquartered in San Jose, California. Investors include New Enterprise Associates, Draper Fisher Jurvetson and Advanced Technology Ventures.
Planful is the pioneer of financial performance management cloud software. The Planful platform is used by the Office of the CFO around the globe to streamline business-wide planning, budgeting, consolidations, reporting, and visual analytics. Planful empowers users to plan confidently, close faster, and report accurately. More than 1,000 customers, including Boston Red Sox, Del Monte, TGI Friday’s, and 23andMe, rely on Planful to accelerate cycle times, increase productivity, and improve accuracy across the end-to-end FP&A process. Planful is a private company backed by Vector Capital, a leading global private equity firm. Learn more at www.planful.com.
Nuvaira is a new alternative COPD treatment option that specializes in developing devices for treating lung diseases. Nuvaira is currently working on a novel catheter-based system that has the potential to improve lung function, exercise capacity, and quality of life for patients with chronic obstructive pulmonary disease. It was founded in 2008 and headquartered in Minneapolis, Minnesota.
Catabasis Pharmaceuticals is a biopharmaceutical company located in Cambridge, Massachusetts focused on the discovery and development of innovative drugs to treat inflammatory conditions. Their platform technology enables the discovery and development of small molecules that simultaneously and specifically target pathways in the inflammatory response. The Catabasis platform will lead to the development of a novel mechanism of action therapies to safely and effectively treat inflammatory diseases.
Planful is the pioneer of financial performance management cloud software. The Planful platform is used by the Office of the CFO around the globe to streamline business-wide planning, budgeting, consolidations, reporting, and visual analytics. Planful empowers users to plan confidently, close faster, and report accurately. More than 1,000 customers, including Boston Red Sox, Del Monte, TGI Friday’s, and 23andMe, rely on Planful to accelerate cycle times, increase productivity, and improve accuracy across the end-to-end FP&A process. Planful is a private company backed by Vector Capital, a leading global private equity firm. Learn more at www.planful.com.
GluMetrics, Inc., a medical device company, develops tools that enable clinicians to implement a care paradigm for critically ill patients. Its products include GluCath, an intravascular continuous glucose monitoring system to measure blood sugar. The company was founded in 2005 and is based in Irvine, California.
Calithera Biosciences is a development-stage pharmaceutical company committed to discovering and developing novel small molecule therapeutics for the treatment of cancer. They are applying Their scientific expertise to build a pipeline of unique anti- cancer drugs that selectively target metabolic and apoptotic pathways critical to tumor growth and survival.
Modria is a developer of an online dispute resolution platform used to process and resolve customer disputes related to eCommerce. It serves tangible goods and service marketplaces, payment networks, medium and large online merchants, government agencies, and classified sites. Chittu Nagarajan and Colin Rule founded Modria in 2011, with its headquarters in San Jose in California with an additional office in Chennai in India. It operates as a subsidiary of Tyler Technologies as of May 30, 2017.
Thrasos is a bio-therapeutics company focused on the discovery and development of targeted therapies for the prevention and treatment of severe organ failure, with a principle focus on kidney disease. The Company's lead therapeutic program, THR-184, is focused on the prevention and treatment of acute kidney injury (AKI). The Company also has a preclinical development program for treating chronic kidney disease (CKD).
Fuze is a global, cloud-based unified communications platform that empowers productivity and delivers insights across the enterprise by enabling simplified business voice communications, flexible video conferencing, and always-on collaboration. Fuze allows the modern, mobile workforce to seamlessly communicate anytime, anywhere, across any device. Fuze was acquired by 8x8.
Nuvaira is a new alternative COPD treatment option that specializes in developing devices for treating lung diseases. Nuvaira is currently working on a novel catheter-based system that has the potential to improve lung function, exercise capacity, and quality of life for patients with chronic obstructive pulmonary disease. It was founded in 2008 and headquartered in Minneapolis, Minnesota.
QuickPay was founded in 2010 with a vision to leverage trends in mobile technology to remove the pain and hassle of finding, accessing, and paying for parking and transportation. Their revolutionary QP QuickPay mobile parking platform offers users one mobile parking application that works across all parking environments — drivers can even raise parking gates using their mobile phones — and gives parking owners and operators an efficient way to enable mobile parking across all their assets with a single integrated solution. Today drivers can use QP QuickPay and a mobile phone to find and pay for parking at hundreds of locations across the U.S., with new locations being added continually.
EndoGastric Solutions is a medical device company developing and commercializing innovative, evidence-based, incision-less surgical technology for the treatment of GERD.
EndPlay is a leading provider of SaaS Content Management, Engagement and Monetization solutions delivered in the cloud. Powered by its unique 'Intelligent Rendering' technology, EndPlay's end-to-end Platform provides a streamlined user experience that empowers clients to seamlessly produce, manage and instantly deliver content optimized for virtually any device. The company's extensible architecture and integrated partners ensure EndPlay clients can expand, engage, monetize and leverage their content management solution against the complexities facing all brands in the era of Big Data and Quantum Content. Enterprise clients in media, entertainment, consumer packaged goods (CPG) and education verticals have turned to EndPlay's experienced Client Services team to support collaboration, implementation and optimization of their EndPlay solutions. EndPlay’s commitment to innovation and customer-centric approach enables clients to stay ahead of their competition, increase audience engagement, and future-proof their digital business investment. All EndPlay associates are certified to meet the company's rigorous standards of customer service. Partners and clients can also leverage EndPlay's certification process to increase platform productivity and achieve business goals. EndPlay is headquartered in Los Angeles, California with regional offices in Florida and New Jersey, and currently expanding to Europe and Asia. For more information, visit www.endplay.com.
EndoGastric Solutions is a medical device company developing and commercializing innovative, evidence-based, incision-less surgical technology for the treatment of GERD.
EndoGastric Solutions is a medical device company developing and commercializing innovative, evidence-based, incision-less surgical technology for the treatment of GERD.
GluMetrics, Inc., a medical device company, develops tools that enable clinicians to implement a care paradigm for critically ill patients. Its products include GluCath, an intravascular continuous glucose monitoring system to measure blood sugar. The company was founded in 2005 and is based in Irvine, California.
Solar Junction is a manufacturer of high efficiency III-V multi-junction solar cells based on ASLAM ™ materials. The company is dedicated to providing the industry’s highest efficiency solar cells to enable CPV as a cost effective energy solution. Founded in 2007, Solar Junction is headquartered in San Jose, California. Investors include New Enterprise Associates, Draper Fisher Jurvetson and Advanced Technology Ventures.
Catabasis Pharmaceuticals is a biopharmaceutical company located in Cambridge, Massachusetts focused on the discovery and development of innovative drugs to treat inflammatory conditions. Their platform technology enables the discovery and development of small molecules that simultaneously and specifically target pathways in the inflammatory response. The Catabasis platform will lead to the development of a novel mechanism of action therapies to safely and effectively treat inflammatory diseases.
Actifio delivers Enterprise Data-as-a-Service to hundreds of global enterprise customers and service provider partners in more than 30 countries. Actifio helps hundreds of global enterprise customers and service provider partners in more than 30 countries around the world virtualize their data, just as they virtualized their servers and networks. Their Virtual Data Pipeline™ technology decouples data from infrastructure, enabling dramatic improvements in business resiliency, agility, and access to the cloud. Actifio replaces siloed data management applications with a radically simple, application-centric, SLA-driven approach that lets customers capture data from production applications, manage it more economically, and use it when and where they need. The result is enterprise data available for any use, anytime, anywhere, for less.
Calithera Biosciences is a development-stage pharmaceutical company committed to discovering and developing novel small molecule therapeutics for the treatment of cancer. They are applying Their scientific expertise to build a pipeline of unique anti- cancer drugs that selectively target metabolic and apoptotic pathways critical to tumor growth and survival.
Founded in 2009 by Marty Kagan and Julien Coulon, two veterans of web hosting and content delivery market, Cedexis optimizes web performance across data centers, delivery networks and clouds for companies that want to reach new global markets. With Cedexis, companies can comparatively assess worldwide cloud performance and availability for informed vendor selection and making cost-and-performance tradeoffs. Cedexis also provides adaptive automation for dynamically optimizing traffic across clouds, data centers and delivery networks to dynamically match the best-performing clouds with local demand. Since revenue conversions and brand experience are directly tied to online performance, media, retail and consumer branded companies rely on Cedexis to ensure 100% availability, fast page loads, downloads and transactions to drive traffic and revenue at lower cost and risk. Cedexis is headquartered in Portland (OR) and Paris (EMEA) with offices in San Francisco (CA), London (UK) and sales representatives in Germany, Japan, Israel and Brazil.
PowerVision is a private company focused on developing a novel accommodating intraocular lens, which is designed to restore True AccommodationTM. Their innovative FluidVisionTM accommodating intraocular lens (IOL) is poised to help individuals affected by presbyopia and/or cataracts regain the ability to dynamically adjust focus for clear vision at all distances. Fifty years ago, vision correction surgery was changed forever by the invention of the intraocular lens, which is used to treat a cataract – a clouding and hardening of the dime-sized, normally clear, crystalline lens inside your eye which can rob you of your vision in your 60’s, 70’s and 80’s. PowerVision set out to dramatically improve vision correction surgery again. They began the development of their FluidVision IOL, which mimics the way a healthy eye works and can restore clear vision at all distances, near, far, and everywhere in between. It uses a tiny amount of fluid inside the lens and natural eye muscles to change shape and adjust focus just the way your healthy eye does. For the more than 20 million people with cataracts in the U.S. and, ultimately, the more than 90 million with Presbyopia – the loss of ability to focus up close that affects people in their 40’s and 50’s – the FluidVision lens can potentially give them freedom from ever needing glasses, contacts or any vision correction procedure again.
Verastem Oncology is a late-stage development biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition, FAK inhibition, and KRAS G12D inhibition.
Only Evergage’s real-time personalization platform delivers The Power of 1, enabling digital marketers to transform the dream of 1:1 customer engagement into reality. Combining in-depth behavioral analytics with customer data, Evergage provides the one platform you need to systematically understand and interact with each person that visits your site or uses your app – one at a time, “in the moment” and at scale – to deliver a maximally relevant, individualized experience. Personalization is the future of digital marketing, and we believe it should be easy for marketers – without the need for developers or IT – to understand their audiences and respond in real time with the most engaging experiences and the most relevant recommendations. Our customers delight their visitors, prospects and customers every day, building valuable relationships that lead to greater revenues and customer loyalty. Evergage has delivered personalized experiences to more than 2 billion web visitors and users of over 150 organizations, including Academy Sports+Outdoors, Endurance International Group, Intuit, Publishers Clearing House, Rue La La, Zumiez and more. Founded in 2010 and based in Somerville, MA, Evergage is a two-time winner in the Golden Bridge Awards, Stevie American Business Awards, Best in Biz Awards and MITX Awards; a two-time BostInno “50 on Fire” finalist; and a TechCrunch Disrupt finalist.
PolyRemedy offers integrated wound management systems designed to increase consistency by extending wound care expertise to the point of care. The PolyRemedy Personalized Woundcare System (PWS) enables clinicians to document care through easy-to-use, web-based assessment tools and order personalized wound dressings, while also providing critical and unprecedented visibility into wound care data. It was founded in 2004 and is headquartered in Concord, Massachusetts.
[x+1] is the only marketing technology company recognized as a leader in both the Forrester DMP and DSP Wave Reports. [x+1] Origin Platform is a programmatic marketing hub that empowers the world's best brands to engage audiences in progressively relevant conversations across a full spectrum of paid and owned digital channels. [x+1] Origin Data Management Platform (DMP), powered by the Predictive Optimization Engine (POE™) and a wholly-integrated DSP, blends first and third-party data with predictive decisioning to engage audiences across online display, mobile web, apps, email, site, and other digital channels. This is why the world’s best brands including seven of the top financial services advertisers rely on [x+1] for their programmatic marketing. The company is headquartered in New York City with offices in Connecticut, Illinois, Michigan and California. For more information visit www.xplusone.com
Catabasis Pharmaceuticals is a biopharmaceutical company located in Cambridge, Massachusetts focused on the discovery and development of innovative drugs to treat inflammatory conditions. Their platform technology enables the discovery and development of small molecules that simultaneously and specifically target pathways in the inflammatory response. The Catabasis platform will lead to the development of a novel mechanism of action therapies to safely and effectively treat inflammatory diseases.
Actifio delivers Enterprise Data-as-a-Service to hundreds of global enterprise customers and service provider partners in more than 30 countries. Actifio helps hundreds of global enterprise customers and service provider partners in more than 30 countries around the world virtualize their data, just as they virtualized their servers and networks. Their Virtual Data Pipeline™ technology decouples data from infrastructure, enabling dramatic improvements in business resiliency, agility, and access to the cloud. Actifio replaces siloed data management applications with a radically simple, application-centric, SLA-driven approach that lets customers capture data from production applications, manage it more economically, and use it when and where they need. The result is enterprise data available for any use, anytime, anywhere, for less.
EndoGastric Solutions is a medical device company developing and commercializing innovative, evidence-based, incision-less surgical technology for the treatment of GERD.
NeuroVista Corporation is a medical device company pioneering new technologies for the management and treatment of epilepsy, a condition that affects roughly 3 million people in the United States. The defining characteristic of epilepsy is recurrent seizures that strike without warning. Symptoms may range from brief suspension of awareness, to loss of consciousness, to violent convulsions. Unlike other neurological conditions, such as stroke or Alzheimer's disease which tend to develop later in life, epilepsy often affects people in the prime of their lives, with the majority between 15 and 64 years of age.
Calxeda provides revolutionary efficiency to the data center. Leveraging ultra-low power technology from ARM, servers built on Calxeda’s silicon and software platform consume a fraction of the power and space of today’s best-in-class servers, enabling data centers to realize significant reduction in capital and operating expenses. The Calxeda platform scales efficiently to thousands of server nodes, with unique network and storage acceleration, and is enhanced with management technology to deliver true “energy-proportional” computing. The result is a stunning breakthrough in performance efficiency, density, and scalability.
Coskata, Inc. is a biology-based renewable energy company, with technology for the production of liquid fuels. Using proprietary microorganisms and transformative bioreactor designs, the company will produce ethanol from a wide variety of input materials to provide economic, environmental, and national security benefits.
Calithera Biosciences is a development-stage pharmaceutical company committed to discovering and developing novel small molecule therapeutics for the treatment of cancer. They are applying Their scientific expertise to build a pipeline of unique anti- cancer drugs that selectively target metabolic and apoptotic pathways critical to tumor growth and survival.
Acceleron Pharma, Inc. operates as a biopharmaceutical company. The company engages in developing, manufacturing, and commercializing novel biotherapeutics that modulate the growth of bone, muscle, fat, and the vasculature to treat musculoskeletal, metabolic, and cancer-related diseases. Its products include ACE-011 Program, a novel bone forming agent that helps to treat cancer-related bone loss; ACE-031 Program that helps to treat diseases involving the loss of muscle mass, strength, and function in diseases, including muscular dystrophy, amyotrophic lateral sclerosis, and cancer-related muscle loss; and ACE-041, a protein therapeutic that binds a member of the growth and differentiation factor family necessary for angiogenesis. It develops therapies based on growth and differentiation factors that regulate the cellular proliferation, differentiation, and survival of a range of tissue types. The company offers treatments for cancer-related bone loss, cancer-related muscle loss, neuromuscular diseases, and metabolic disorders. Acceleron Pharma, Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.
Planful is the pioneer of financial performance management cloud software. The Planful platform is used by the Office of the CFO around the globe to streamline business-wide planning, budgeting, consolidations, reporting, and visual analytics. Planful empowers users to plan confidently, close faster, and report accurately. More than 1,000 customers, including Boston Red Sox, Del Monte, TGI Friday’s, and 23andMe, rely on Planful to accelerate cycle times, increase productivity, and improve accuracy across the end-to-end FP&A process. Planful is a private company backed by Vector Capital, a leading global private equity firm. Learn more at www.planful.com.
Catabasis Pharmaceuticals is a biopharmaceutical company located in Cambridge, Massachusetts focused on the discovery and development of innovative drugs to treat inflammatory conditions. Their platform technology enables the discovery and development of small molecules that simultaneously and specifically target pathways in the inflammatory response. The Catabasis platform will lead to the development of a novel mechanism of action therapies to safely and effectively treat inflammatory diseases.
Solar Junction is a manufacturer of high efficiency III-V multi-junction solar cells based on ASLAM ™ materials. The company is dedicated to providing the industry’s highest efficiency solar cells to enable CPV as a cost effective energy solution. Founded in 2007, Solar Junction is headquartered in San Jose, California. Investors include New Enterprise Associates, Draper Fisher Jurvetson and Advanced Technology Ventures.
EndoGastric Solutions is a medical device company developing and commercializing innovative, evidence-based, incision-less surgical technology for the treatment of GERD.
EndoGastric Solutions is a medical device company developing and commercializing innovative, evidence-based, incision-less surgical technology for the treatment of GERD.
EndoGastric Solutions is a medical device company developing and commercializing innovative, evidence-based, incision-less surgical technology for the treatment of GERD.
Planful is the pioneer of financial performance management cloud software. The Planful platform is used by the Office of the CFO around the globe to streamline business-wide planning, budgeting, consolidations, reporting, and visual analytics. Planful empowers users to plan confidently, close faster, and report accurately. More than 1,000 customers, including Boston Red Sox, Del Monte, TGI Friday’s, and 23andMe, rely on Planful to accelerate cycle times, increase productivity, and improve accuracy across the end-to-end FP&A process. Planful is a private company backed by Vector Capital, a leading global private equity firm. Learn more at www.planful.com.
Ardian is an independent private investment company that provides a diverse range of investment opportunities and responds to clients and believes that the benefits that they contribute should be distributed as widely as possible.
GI Dynamics, Inc., a medical device company, develops therapies for the treatment of type 2 diabetes and related metabolic diseases in the United States. Its products also include EndoBarrier, a non-surgical therapy to treat type 2 diabetes and obesity. The company was founded in 2003 and is based in Lexington, Massachusetts.
Oasys (Osmotic Application Systems) is a privately held Boston, MA based company developing a suite of proprietary energy and resource recovery products to address the growing, global water crisis. Engineered Osmosisâ„¢ (EOâ„¢) is a platform for reducing cost in the production of clean water, power and energy through more efficient and sustainable utilization of resources.
Hydra Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, develops novel drugs to treat pain, inflammation, cardiovascular and other diseases using its expertise in novel ion channels. Hydra's proprietary high throughput screening platforms enable the company to identify and develop drug candidates that address significant unmet medical needs. Hydra's ion channel drug discovery program is currently focused on channels implicated in pain, inflammation, and cardiovascular disease. Hydra's intellectual property portfolio, significant ion channel expertise, and flexible screening systems set it apart from other biopharmaceutical companies. Unlike classical sodium, calcium, or potassium voltage-gated channels Hydra's novel ion channels provide the potential to develop selective and safer ion channel drugs. Hydra has raised significant financing from blue-chip investors since its inception. This prominent group of investors includes Abingworth Ventures, Advanced Technology Ventures, Polaris Ventures, Lilly Bio Ventures, New Enterprise Associates, BioVentures Investors, Biogen Idec, Boston Medical Investors, and MedImmune Ventures.
CombineNet, Inc. is the advanced sourcing technology company, with over 10 years of delivering strong value to mid-sized and global organizations alike, across nearly all industries, as they make supplier and spend decisions on products and services. CombineNet's product ASAP (Advanced Sourcing Application Platform) is a web-based software-as-a-service solution that allows sourcing teams in any spend category to speed and simplify the creation, launch, and management of sourcing events of any size, scale, or complexity.
Coskata, Inc. is a biology-based renewable energy company, with technology for the production of liquid fuels. Using proprietary microorganisms and transformative bioreactor designs, the company will produce ethanol from a wide variety of input materials to provide economic, environmental, and national security benefits.
Anagran's flow-based traffic management products eliminate the potentially crippling effects of network congestion to enable video, voice, data and wireless traffic to economically scale with flawless quality over converged IP networks. Anagran's products protect all key network traffic by managing end-to-end flows based on their behavior to ensure required quality and performance levels. Its products dynamically manages all network traffic regardless of application, protocol, or format, without using invasive, performance-limiting deep packet inspection(DPI) techniques. Service providers and enterprises can consistently deliver the highest levels of guaranteed performance and quality while significantly reducing capital equipment and recurring network costs. Anagran was founded by Internet pioneer Dr. Larry Roberts, recognized as one of the founding fathers of the Internet.
Valeritas is a medical technology company committed to developing and commercializing innovative drug delivery solutions that contribute to clinical and humanistic outcomes for patients, with an initial focus on the treatment of diabetes. Valeritas' medical technologies portfolio is headlined by the h-Patch technology. The first use of the h-Patch technology will be the V-Go disposable insulin delivery device for continuous delivery both at a preset basal rate and for on-demand bolus dosing at mealtimes. The V-Go is a simple-to-use, once-daily, disposable insulin delivery device that provides a preset basal rate and on-demand bolus dosing for mealtime coverage via a mealtime insulin. The V-Go will enable the millions suffering from Type 2 diabetes to conveniently and discreetly deliver insulin throughout the day bolus dose on-demand around mealtimes. The h-Patch technology is also being developed to serve as a launching platform for applications across a wide spectrum of medical needs.
Onyx Pharmaceuticals (NASDAQ: ONXX) is a biopharmaceutical company engaged in the development and commercialization of innovative therapies for improving the lives of people with cancer and other serious diseases.
ChannelAdvisor develops a cloud-based multichannel commerce solution for brands and retailers. It streamlines e-commerce operations, expands to new channels, and grows sales from a centralized platform. The company helps brands and retailers worldwide improve their online performance by expanding sales channels, connecting with consumers across the entire buying cycle, optimizing their operations for peak performance, and providing actionable analytics to improve competitiveness.
GluMetrics, Inc., a medical device company, develops tools that enable clinicians to implement a care paradigm for critically ill patients. Its products include GluCath, an intravascular continuous glucose monitoring system to measure blood sugar. The company was founded in 2005 and is based in Irvine, California.
AltaRock Energy is a renewable energy development company focused on the research and development of Engineered Geothermal Systems (“EGSâ€). AltaRock has filed patent applications for a portfolio of patents in the EGS area and holds exclusive licenses for related intellectual property. The company has its corporate headquarters in Sausalito, CA and its technology development office in Seattle, WA. Its principals include Don O'Shei, Chief Executive Officer, and Susan Petty, President/Chief Technology Officer and an AltaRock Energy founder.
Qumu is the leading provider of a best-in-class platform to create, manage, secure, distribute and measure the success of live and on demand video for the intelligent enterprise.
Wakonda Technologies was founded in 2005 by Dr. Les Fritzemeier and Professor Ryne Raffaelle of the Rochester Institute of Technology. The company was established to exploit the intersection of their respective skills in metallurgical processing and advanced photovoltaic devices. Wakonda was started in Rochester NY and used the facilities at RIT, Cornell University and several government agencies to conduct proof of concept experiments. In 2008, the company moved to Massachusetts to accelerate product development and early commercialization. Wakonda has received several honors over its short history, winning the first ever Golden Horseshoe Business Challenge in upstate NY and being named the National Renewable Energy Laboratory's Entrepreneur of the Year in 2007.
Solar Junction is a manufacturer of high efficiency III-V multi-junction solar cells based on ASLAM ™ materials. The company is dedicated to providing the industry’s highest efficiency solar cells to enable CPV as a cost effective energy solution. Founded in 2007, Solar Junction is headquartered in San Jose, California. Investors include New Enterprise Associates, Draper Fisher Jurvetson and Advanced Technology Ventures.
Handango provides smartphone applications globally for the [BlackBerry](/organization/blackberry), [Palm](/organization/palm), Windows Mobile, [Symbian OS](http://www.crunchbase.com/organization/symbian-software-ltd), and Linux platforms. Leveraging its 140,000+ apps, network of 23,000+ content partners, and vast distribution network, Handango delivers top-selling mobile applications including games, business and entertainment apps and productivity tools to millions of consumers. Applications can be downloaded via www.handango.com, partner Web sites, SD cards and Handango's proprietary on-device catalog, InHand, the industry's leading content delivery platform that allows consumers to purchase mobile apps directly from their smartphone and download them over the air. Handango's unparalleled content expertise has attracted numerous mobile industry partners including [Microsoft](/organization/microsoft), [Verizon Wireless](/organization/verizon), [T-Mobile](/organization/t-mobile), Alltel, AT&T, 3UK, LG, SoftBank, Sony Ericsson, Samsung, Best Buy, The CarPhone Warehouse, CNET, and AOL.
Hydra Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, develops novel drugs to treat pain, inflammation, cardiovascular and other diseases using its expertise in novel ion channels. Hydra's proprietary high throughput screening platforms enable the company to identify and develop drug candidates that address significant unmet medical needs. Hydra's ion channel drug discovery program is currently focused on channels implicated in pain, inflammation, and cardiovascular disease. Hydra's intellectual property portfolio, significant ion channel expertise, and flexible screening systems set it apart from other biopharmaceutical companies. Unlike classical sodium, calcium, or potassium voltage-gated channels Hydra's novel ion channels provide the potential to develop selective and safer ion channel drugs. Hydra has raised significant financing from blue-chip investors since its inception. This prominent group of investors includes Abingworth Ventures, Advanced Technology Ventures, Polaris Ventures, Lilly Bio Ventures, New Enterprise Associates, BioVentures Investors, Biogen Idec, Boston Medical Investors, and MedImmune Ventures.
Aperio is the leading provider of digital pathology solutions in hospitals, reference labs, and pharmaceutical and research institutions across the world. Today, our affordable and complete product portfolio improves patient care by enhancing quality assurance, delivering more efficient workflows, facilitating access to new and more targeted therapies, and improving pathologists' skills via lifelong education. Our comprehensive product line features our ScanScope® scanners, Spectrum™ image management (PACS) software, SecondSlide® slide sharing service for pathology, and image analysis tools and services. Aperio's products are FDA cleared for specific clinical applications, and are intended for research and education use for other applications.
Coskata, Inc. is a biology-based renewable energy company, with technology for the production of liquid fuels. Using proprietary microorganisms and transformative bioreactor designs, the company will produce ethanol from a wide variety of input materials to provide economic, environmental, and national security benefits.
PolyRemedy offers integrated wound management systems designed to increase consistency by extending wound care expertise to the point of care. The PolyRemedy Personalized Woundcare System (PWS) enables clinicians to document care through easy-to-use, web-based assessment tools and order personalized wound dressings, while also providing critical and unprecedented visibility into wound care data. It was founded in 2004 and is headquartered in Concord, Massachusetts.
IMMI, a San Mateo, CA-based mobile-based ad tracking and research firm. The IMMI phone randomly samples 10 seconds of room audio every 30 seconds...these sample are uploaded continuously to the IMMI servers. IMMI also tracks all local TV and radio outlets, and then compares mobile-uploaded signatures with the IMMI-monitored TV and radio broadcasts. The mobile phone also receives a signal from an IMMI "Bluetooth beacon" when the panel member is at home, so the servers can interpret media exposure as "in" or "out-of-home."
Anagran's flow-based traffic management products eliminate the potentially crippling effects of network congestion to enable video, voice, data and wireless traffic to economically scale with flawless quality over converged IP networks. Anagran's products protect all key network traffic by managing end-to-end flows based on their behavior to ensure required quality and performance levels. Its products dynamically manages all network traffic regardless of application, protocol, or format, without using invasive, performance-limiting deep packet inspection(DPI) techniques. Service providers and enterprises can consistently deliver the highest levels of guaranteed performance and quality while significantly reducing capital equipment and recurring network costs. Anagran was founded by Internet pioneer Dr. Larry Roberts, recognized as one of the founding fathers of the Internet.
PowerVision is a private company focused on developing a novel accommodating intraocular lens, which is designed to restore True AccommodationTM. Their innovative FluidVisionTM accommodating intraocular lens (IOL) is poised to help individuals affected by presbyopia and/or cataracts regain the ability to dynamically adjust focus for clear vision at all distances. Fifty years ago, vision correction surgery was changed forever by the invention of the intraocular lens, which is used to treat a cataract – a clouding and hardening of the dime-sized, normally clear, crystalline lens inside your eye which can rob you of your vision in your 60’s, 70’s and 80’s. PowerVision set out to dramatically improve vision correction surgery again. They began the development of their FluidVision IOL, which mimics the way a healthy eye works and can restore clear vision at all distances, near, far, and everywhere in between. It uses a tiny amount of fluid inside the lens and natural eye muscles to change shape and adjust focus just the way your healthy eye does. For the more than 20 million people with cataracts in the U.S. and, ultimately, the more than 90 million with Presbyopia – the loss of ability to focus up close that affects people in their 40’s and 50’s – the FluidVision lens can potentially give them freedom from ever needing glasses, contacts or any vision correction procedure again.
Acceleron Pharma, Inc. operates as a biopharmaceutical company. The company engages in developing, manufacturing, and commercializing novel biotherapeutics that modulate the growth of bone, muscle, fat, and the vasculature to treat musculoskeletal, metabolic, and cancer-related diseases. Its products include ACE-011 Program, a novel bone forming agent that helps to treat cancer-related bone loss; ACE-031 Program that helps to treat diseases involving the loss of muscle mass, strength, and function in diseases, including muscular dystrophy, amyotrophic lateral sclerosis, and cancer-related muscle loss; and ACE-041, a protein therapeutic that binds a member of the growth and differentiation factor family necessary for angiogenesis. It develops therapies based on growth and differentiation factors that regulate the cellular proliferation, differentiation, and survival of a range of tissue types. The company offers treatments for cancer-related bone loss, cancer-related muscle loss, neuromuscular diseases, and metabolic disorders. Acceleron Pharma, Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.
Apprion delivers intelligent, industrial applications and services for the process manufacturing industry. Apprion extends and manages the Industrial Internet of Things with the only open, industrial application platform – the ION System. The ION System includes multiple industrial applications that address all of your critical safety, security, compliance and performance needs for Communications, Condition Monitoring, Asset & Personnel Location, Video, and Workforce Mobility.
Helixis, Inc. is a company that develops low-cost molecular diagnostic products.